Mechanistically, SAH-JGZ4 disturbed the in vivo interactions of EGFR–TRIB3 and EGFR–PKCα, and suppressed the expression of EGFR and PKCα in the inoculated tumor tissues (Fig. 7e). Here, PRKCA is linked to neoplasm.